Extracted from this filing and checked against the source text.
Material AgreementsSEC 8-K Item 1.01/1.02confidence 0.98
TAO Synergies Inc. entered into Securities Purchase Agreement with certain accredited investors valued at $15 million (effective 2022-11-17).
Action
entry
Agreement
equity purchase
Counterparty
certain accredited investors
Value
$15 million
Effective
2022-11-17
Exact text from the filing
On November 17, 2022, Synaptogenix, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain accredited investors (the “Investors”), pursuant to which it agreed to sell to the Investors (i) an aggregate of 15,000 shares of the Company’s newly-designated Series B convertible preferred stock with a stated value of $1,000 per share, initially convertible into up to 1,935,485 shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) at a conversion price of $7.75 per share (the “Preferred Shares”), and (ii) warrants to acquire up to an aggregate of 1,935,485 shares of Common Stock (the “Warrants”) (collectively, the “Private Placement”).
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.